ABSTRACT The vasodilator effects of nitroglycerin (NTG) are mediated via activation of guanylate cyclase; this process is believed to require the availability of free sulfhydryl groups. Previous studies in man have shown that the sulfhydryl donor N-acetylcysteine (NAC) potentiates the systemic and coronary vasodilator effects of NTG. Furthermore, interaction of NTG and NAC may lead to the formation of S-nitroso-NAC, which strongly inhibits platelet aggregation. The effects of intravenous NTG combined with intravenous NAC (5 g 6 hourly) were compared with those of intravenous NTG alone in a double-blind trial in 46 patients with severe unstable angina pectoris unresponsive to conventional treatment, which included calcium antagonists and cutaneous nitrates in all but one patient. Treatment with NTG/NAC (24 patients) and that with NTG alone (22 patients) was associated with a similar frequency of episodes of chest pain and of increments in NTG infusion rate for pain control (10 vs 17; p= NS). The NTG/NAC group had a significantly lower incidence of acute myocardial infarction than the NTG/placebo group (three vs 10 patients; p =.013). Symptomatic hypotension occurred frequently in the NTG/NAC group (seven vs 0 patients; p = .006). Lactate-pyruvate ratios and venous NTG concentrations were not significantly affected by NAC. Subsequently, another 20 consecutive patients were treated with intravenous NTG and continuously infused NAC (10 g/day). Seven remained pain free during the first 24 hr of NTG infusion; 11 required increments in NTG infusion rate for pain control. Acute myocardial infarction occurred in one patient, while none developed symptomatic hypotension. It is concluded that combined administration of NTG and NAC may augment the clinical efficacy of NTG, particularly by preventing acute myocardial infarction. However, the risk of development of hypotension with combined NTG/NAC is increased when NAC is administered by rapid intravenous infusion.
INTRAVENOUSLY INFUSED nitroglycerin (NTG) has been shown to be useful in the management of patients with severe unstable angina pectoris unresponsive to other treatment measures. [1] [2] [3] [4] [5] While many patients experience marked symptomatic improvement with intravenous NTG, a significant proportion continue to experience episodes of angina pectoris at rest. In some patients, infusion rates of NTG must be increased repeatedly to achieve control of symptoms Indications for withdrawal from the study were persisting severe ischemia occurring despite increased NTG infusion rates and thought to require initiation of intra-aortic balloon counterpulsation, emergency coronary artery bypass grafting or coronary angioplasty, or the occurrence of severe adverse reactions to NTG or NAC. The prospectively defined primary end point of the study was control of symptomatic ischemia, determined by: (1) total number of episodes of chest pain, and (2) number of increments of NTG infusion rate for pain control.
The secondary end points of the study were: (1) incidence of acute myocardial infarction, since it was anticipated that elevation of plasma CK levels would occur in 25% to 35% of the patients studied,29 33 and (2) adverse effects, particularly hypotension.
On the basis of the primary end point, it was intended that 70 patients should be enrolled in the study. Furthermore, we planned to review the study when two-thirds of this sample size had been completed. At the time of this review (after 46 17  50  18  68  19  52  20  67  21  58  22  67  23  58  24  47  Placebo group  1  57  2  62  3  49  4  35  5  46  6  58  7  65  8  62  9  50  10  56  11  72  12  40  13  55  14  64  15  54  16  61  17  73  18  41  19  59  20  64  21  57  22 63 Increases in NTG infusion rate for control of chest pain were necessary in eight patients in the NAC group and 11 patients in the placebo group. A total of 10 increases occurred in the NAC group vs 17 in the placebo group (p = NS). Increases in NTG infusion rate were required in one other patient in each group for control of persistent hypertension. were relatively small, as judged by peak CK levels of less than 2500 IU/liter, in all but one patient, in whom cardiogenic shock developed rapidly.
The effect of NAC on responsiveness to NTG may be predicted from a number of studies in vitro17' 25 Furthermore, NAC has been shown to markedly potentiate the antiplatelet effects of NTG, probably via the formation of S-nitroso-NAC.28 Each of these factors is of potential importance in the management of patients with severe unstable angina pectoris, in whom there is a high incidence of associated intracoronary nonocclusive thrombi,4' as well as an increased incidence of coronaryvasospasm.33 Finally, there is increasing evidence that sulfhydryl donors such as NAC may protect against myocardial damage and dysfunction during periods of ischemia and 42, 43 reperfusion.424
Analysis of the frequency of episodes of ischemic pain revealed no difference between the NAC and placebo groups, while the trend toward fewer increments in NTG infusion rate in the NAC group fell short of being statistically significant. This may represent type IL error, or alternatively, the frequency of discrete episodes of ischemic pain in the placebo group may have been reduced somewhat because of the frequent development of acute myocardial infarction in these patients. The question of NTG/NAC effects on the frequency of ischemia therefore remains unanswered at this stage, and needs to be addressed in further studies with a larger sample size.
Somewhat unexpectedly, on an intention-to-treat basis, three patients in the NAC group and 10 in the placebo group developed acute myocardial infarction during the study period; this difference was statistically significant. Of the three patients in the NAC group in whom acute myocardial infarction occurred, only two received NAC (see above). In both of these cases, onset of infarction followed severe hypotension, which developed approximately 60 min after the infusion of NAC. It is therefore possible that infarction in these patients was precipitated by potentiation by NAC of the hemodynamic effects of NTG. This is supported by the observation that most cases of hypotension in the NAC group occurred 30 to 60 min after the infusion of NAC. 
